Neurotoxicity Assay (RA-differentiated Human SH-SY5Y cells), Cell Viability SafetyScreen Assay – TW
OVERVIEW
DOCUMENTS/REFERENCES
Biological Information
Background Information:
Neurotoxicity refers to the damage and disruption of nervous system function or structure caused by exogenous compounds, potentially leading to acute or chronic toxic effects, particularly during critical developmental stages. The SH-SY5Y human neuroblastoma cell line has been widely utilized as an in vitro model for neurotoxicity studies due to its adaptability. It can be maintained as proliferative neuroblasts or induced to differentiate into neuron-like cells, mimicking aspects of neuronal function and morphology. This differentiation capability enables assessment of neurotoxicity in both immature and mature neuronal states. As a human-derived neuronal-like model, differentiated SH-SY5Y cells provide a physiologically relevant platform for neurotoxicological screening, supporting the evaluation of drug safety, chemical risk assessment, and mitigation of adverse effects on the nervous system. In this assay, differentiated SH-SY5Y cells are used, and cell viability is assessed to indicate the potential neurotoxicity of the test samples.
Family:
Cell Based Phenotypic
Organism:
Human
Construct Details:
Endogenous
Cell Type:
SH-SY5Y
Assay Information
Assay Type:
Functional
Assay Sub Type:
Cell Based
Functional Mode:
Antagonist
Detection Method:
Luminescence
Platform:
Plate reader
Measured Response:
Luminescence
Testing Information
Procedure Summary:
SH-SY5Y cells are seeded in the 96-well half area plate and differentiated for 7 days at 37°C, 5% CO2. Test compound and/or vehicle is then added for an additional 72 hours at 37°C, 5% CO2. After incubation, cell viability is evaluated by detecting ATP levels in living cells and the luminescence intensity is measured using luminescence reader. Decrease of 50 percent or more (≥50%) in luminescence intensity relative to vehicle treated control indicates significant neurotoxicity. 10 μM Staurosporine is defined as 100% inhibition.
Incubation:
3 d at 37°C
Control Inhibitor:
Staurosporine
Criteria For Significance:
≥ 50% Decrease in luminescence intensity relative to vehicle control
Test Concentration / Dose:
Compounds are screened at 10, 3, 1, 0.3, 0.1, 0.03, 0.01 and 0.003 μM
Test Sample Requirements:
75 μl of 10 mM stock or 1 mg (pre-weighed) powder (assuming FW ≦500 and purity 100%)
Minimum Order Quantity:
16
Turnaround Time
Standard:
30 Business Days
Reference Compound Data
Clinical Relevance
Therapeutic Area:
CNS/Addiction/Pain
Additional Information
Brand:
Panlabs
Testing Location:
Taiwan - Taipei
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
